Subscribe

AstraZeneca PLC (AZN.L)

GBp12,538.00 -72.00 (-0.57%)
GB LSE Healthcare Drug Manufacturers - General
Address 1 Francis Crick Avenue CB2 0AA
Cambridge, GB
CEO Pascal Claude Roland Soriot
Website astrazeneca.com
IPO 1993-05-21
ISIN GB0009895292

Explore sections of this company profile

Also trades on Deutsche Börse · ZEG.DE (EUR) London Stock Exchange · AZN.L (GBp) New York Stock Exchange · AZN (USD) Other OTC · AZNCF (USD) Stockholm Stock Exchange · AZN.ST (SEK)
Description

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.

News Sentiment (7d)
50 Neutral

Based on only 1 article — low confidence

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp12,538.00 -72.00 (-0.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.21
Float Shares
1.54B
Free Float %
99.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.16% +3.21% -8.13% -8.92% +2.05% -0.15% +35.27% +14.75% +75.37% +249.49% -77.06%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (36 ratings, all time) Buy
Price Targets & DCF
Current price
12,538.00
DCF (Unlevered) 132,020.37 +953.0%
DCF (Levered) 87,052.87 +594.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 80% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 16 0
Hold 3 0
Sell 1 0
Strong Sell 1 0
Quality scores
Altman Z-Score
3.61
Safe zone
Piotroski F-Score
9 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Drug Manufacturers - General: +6.6%
    +11.0% ★ Q1'26: +9.5% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +48.3% ★ Q1'26: +2.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +15.5% ★ Q1'26: +11.9% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - General: +19.4%
    +24.0% ★ Q1'26: +28.2% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - General: +10.2%
    +16.0% ★ Q1'26: +18.4% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -0.1% ★ Q1'26: +0.0% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    1.49× Q1'26: 1.49× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.22) × ERP
WACC = 91% × Ke + 9% × Kd (5.7%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 131,941.52 Current price: 12,538.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
22 Rev. Ana.
14 EPS Ana. 		Dec 2027
22 Rev. Ana.
14 EPS Ana. 		Dec 2028
10 Rev. Ana.
7 EPS Ana. 		Dec 2029
15 Rev. Ana.
8 EPS Ana. 		Dec 2030
11 Rev. Ana.
12 EPS Ana.
Revenue
32.47B
est: 33.98B (-4.4%)
28.35B
est: 28.44B (-0.3%)
26.74B
est: 26.09B (+2.5%)
25.89B
est: 26.60B (-2.7%)
23.93B
est: 24.50B (-2.3%)
20.92B
est: 22.63B (-7.6%)
23.45B
est: 21.96B (+6.8%)
20.99B
est: 23.16B (-9.4%)
24.50B
est: 23.57B (+3.9%)
29.27B
est: 26.25B (+11.5%)
37.11B
est: 36.35B (+2.1%)
44.25B
est: 45.15B (-2.0%)
46.58B
est: 62.19B (-25.1%)
52.94B
est: 53.12B (-0.3%)
58.74B
est: 58.58B (+0.3%)
61.54B
60.07B – 62.92B
+5.1% YoY
65.82B
59.30B – 69.16B
+7.0% YoY
70.09B
65.70B – 72.68B
+6.5% YoY
75.57B
70.84B – 78.37B
+7.8% YoY
80.72B
75.66B – 83.70B
+6.8% YoY
EBITDA
14.30B
est: 13.73B (+4.2%)
10.53B
est: 12.13B (-13.2%)
6.62B
est: 8.95B (-26.0%)
4.71B
est: 7.59B (-38.0%)
5.96B
est: 3.88B (+53.5%)
5.92B
est: 5.14B (+15.3%)
5.64B
est: 5.08B (+10.9%)
5.34B
est: 5.32B (+0.4%)
5.24B
est: 5.59B (-6.2%)
8.04B
est: 5.19B (+54.8%)
4.59B
est: 5.83B (-21.3%)
8.63B
est: 6.54B (+31.9%)
13.20B
est: 32.75B (-59.7%)
14.86B
est: 28.01B (-47.0%)
19.83B
est: 30.85B (-35.7%)
32.42B
31.64B – 33.14B
+5.1% YoY
34.67B
31.23B – 36.43B
+7.0% YoY
36.92B
34.60B – 38.28B
+6.5% YoY
39.81B
37.31B – 41.28B
+7.8% YoY
42.52B
39.85B – 44.09B
+6.8% YoY
EBIT
12.37B
est: 11.90B (+4.0%)
8.18B
est: 10.71B (-23.6%)
3.83B
est: 7.44B (-48.6%)
1.63B
est: 3.77B (-56.9%)
3.37B
est: 1.98B (+69.6%)
3.82B
est: 3.83B (-0.1%)
3.08B
est: 4.63B (-33.5%)
2.70B
est: 3.73B (-27.5%)
2.45B
est: 3.73B (-34.4%)
4.96B
est: 3.27B (+51.9%)
562.01M
est: 3.67B (-84.7%)
3.39B
est: 4.12B (-17.8%)
8.18B
est: 27.96B (-70.8%)
9.90B
est: 23.91B (-58.6%)
14.10B
est: 26.34B (-46.5%)
27.67B
27.01B – 28.29B
+5.1% YoY
29.60B
26.67B – 31.10B
+7.0% YoY
31.52B
29.54B – 32.68B
+6.5% YoY
33.98B
31.85B – 35.24B
+7.8% YoY
36.30B
34.02B – 37.64B
+6.8% YoY
Net Income
9.65B
est: 8.33B (+15.8%)
6.32B
est: 8.36B (-24.3%)
2.66B
est: 5.75B (-53.8%)
1.20B
est: 2.60B (-53.7%)
2.74B
est: 1.15B (+138.9%)
3.18B
est: 2.63B (+21.1%)
3.13B
est: 3.30B (-5.2%)
2.05B
est: 3.05B (-32.8%)
1.34B
est: 2.37B (-43.5%)
3.39B
est: 1.49B (+127.2%)
109.85M
est: 1.68B (-93.4%)
3.28B
est: 6.16B (-46.8%)
6.06B
est: 8.15B (-25.7%)
6.89B
est: 12.61B (-45.4%)
10.23B
est: 14.04B (-27.2%)
15.59B
14.96B – 16.22B
+11.0% YoY
18.98B
16.72B – 19.08B
+21.8% YoY
19.61B
18.01B – 20.55B
+3.3% YoY
22.47B
20.64B – 23.55B
+14.6% YoY
25.09B
23.05B – 26.30B
+11.7% YoY
SGA
9.81B
est: 10.74B (-8.6%)
8.77B
est: 9.10B (-3.6%)
9.22B
est: 8.70B (+6.0%)
10.43B
est: 9.33B (+11.9%)
9.14B
est: 9.79B (-6.7%)
7.49B
est: 8.93B (-16.1%)
8.11B
est: 7.60B (+6.6%)
8.32B
est: 7.76B (+7.1%)
9.56B
est: 9.34B (+2.4%)
10.24B
est: 10.02B (+2.2%)
11.36B
est: 11.25B (+1.0%)
13.37B
est: 12.63B (+5.9%)
14.36B
est: 19.32B (-25.7%)
15.21B
est: 16.08B (-5.4%)
20.51B
est: 18.20B (+12.7%)
19.12B
18.66B – 19.54B
+5.1% YoY
20.45B
18.42B – 21.48B
+7.0% YoY
21.77B
20.41B – 22.58B
+6.5% YoY
23.48B
22.00B – 24.34B
+7.8% YoY
25.07B
23.50B – 26.00B
+6.8% YoY
EPS
7.10
est: 11.43 (-37.9%)
5.02
est: 10.14 (-50.5%)
2.12
est: 8.32 (-74.5%)
0.96
est: 7.23 (-86.8%)
2.16
est: 4.26 (-49.3%)
2.52
est: 4.19 (-39.8%)
2.47
est: 3.78 (-34.6%)
1.62
est: 3.56 (-54.5%)
1.03
est: 3.47 (-70.3%)
2.58
est: 4.16 (-38.0%)
0.08
est: 5.17 (-98.5%)
2.12
est: 6.83 (-68.9%)
3.91
est: 5.26 (-25.7%)
4.44
est: 8.21 (-45.9%)
6.60
est: 9.15 (-27.9%)
9.95
9.58 – 10.38
+8.8% YoY
11.26
10.70 – 12.22
+13.2% YoY
12.55
11.53 – 13.16
+11.4% YoY
14.39
13.22 – 15.08
+14.6% YoY
16.06
14.76 – 16.84
+11.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-08 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-07 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-06 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-05 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-01 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-30 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-29 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-28 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-27 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-24 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-23 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-22 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-21 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-20 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-17 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-16 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-15 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
10.14B
OE per share TTM
6.50
Owner's Yield
4.85%
Maintenance CapEx ratio
39.13%
Maint CapEx / Avg PPE
25.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
149.5K
Shares Outstanding
1.55B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Pascal Claude Roland Soriot Chief Executive Officer & Executive Director 6M male
Aradhana Sarin Chief Financial Officer & Executive Director 3M —
Clive Green Head of Global Sample Management & Discovery Sciences - R&D and Executive Director — male
David Fredrickson Executive Vice-President of Oncology Haematology Business Unit — male
Elisabeth Bjork Senior VP of Late-Stage Development, Cardiovascular, Renal & Metabolism - BioPharmaceuticals R&D — —
Iskra Reic Executive Vice President of International — female
Jeffrey Pott CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board — male
Jim Weatherall Chief Data Scientist of BioPharmaceuticals R&D — male
Joris Silon Head of Investor Relations — male
Lutz Jermutus Head of Projects — male
Pam Cheng EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board — female
Regina Fritsche-Danielson SVP and Head of Research & Early Dev., Cardiovascular, Renal & Metabolism - BioPharmaceuticals R&D — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General